首页> 外文期刊>Biological chemistry >Two Different Mechanisms for Activation of Cyclic PIP Synthase: by a G Protein or by Protein Tyrosine Phosphorylation
【24h】

Two Different Mechanisms for Activation of Cyclic PIP Synthase: by a G Protein or by Protein Tyrosine Phosphorylation

机译:激活环状PIP合酶的两种不同机制:通过G蛋白或蛋白酪氨酸磷酸化

获取原文
获取原文并翻译 | 示例
           

摘要

The biosynthesis of the functional, endogenous cyclic AMP antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP) is performed by the plasma membrane-bound enzyme cyclic PIP synthase, which combines prostaglandin E (PGE) and activated inositol phosphate (n-IP) to cyclic PIP. The K_m values of the enzyme for the substrates PGE and n-IP are in the micromolar range. The plasma membrane-bound synthease is activated by fluoride, by the stable GTP analog GMP-PNP, by protamine or biguanide, by noradrenaline, and by insulin. The activation by protamine or biguanide and fluoride (10 mM) is additive, which may indicate the presence of two different types of enzyme, comparable to phospholipase C_β and phospholipase C_γ. Plasma membrane-bound cyclic PIP synthease is inhibited by the protein tyrosine kinase inhibitor tyrphostin B46 with an IC_(50) of 1.7 μM. However, the solubilized and gel-filtrated enzyme is no longer inhibited by tyrphostin, indicating that the activity of cyclic PIP synthase is connected with the activity of a membrane-bound protein tyrosine kinase. Cyclic PIP synthase activity of freshly prepared plasma membranes is unstable. Upon freezing and rethawing of liver plasma membranes, this instability is increased about 2-fold. Protein tyrosine phosphatase inhibitors [vanadate, fluoride (50-100 mM)] stabilize the enzyme activity, but protease inhibitors do not, indicating that inactivation of the enzyme is connected with protein tyrosine dephosphorylation. Cyclic PIP synthase is present in all tissues tested, like brain, heart, intestine, kidney, liver, lung, skeletal muscle, spleen, and testis. Apart from liver, cyclic PIP synthase activity in most tissues is rather low, but it can be increased up to 5-fold when protein tyrosine phosphatase inhibitors like vanadate are present in the homogenization buffer. Preincubation of cyclic PIP synthase of liver plasma membranes with the tyrosine kinase src kinase causes a 2-fold increase of cyclic PIP synthase activity, though this is certainly not the physiological role played by src kinase in intact cells. The data indicate that cyclic PIP synthase can be activated by two separate mechanisms: by a G protein or by protein tyrosine phosphorylation.
机译:功能性内源性环状AMP拮抗剂,前列腺素肌醇环状磷酸酯(环状PIP)的生物合成是通过质膜结合酶环状PIP合酶完成的,该酶将前列腺素E(PGE)和活化的磷酸肌醇(n-IP)结合成环状PIP 。底物PGE和n-IP的酶的K_m值在微摩尔范围内。质膜结合的合成酶被氟化物,稳定的GTP类似物GMP-PNP,鱼精蛋白或双胍,去甲肾上腺素和胰岛素激活。鱼精蛋白或双胍和氟化物(10 mM)的激活是累加的,这可能表明存在两种与磷脂酶C_β和磷脂酶C_γ相当的酶。质膜结合的环状PIP合成酶被蛋白质酪氨酸激酶抑制剂tyrphostin B46抑制,IC_(50)为1.7μM。然而,增溶和凝胶过滤的酶不再被酪蛋白抑制,这表明环状PIP合酶的活性与膜结合蛋白酪氨酸激酶的活性有关。新鲜制备的质膜的环状PIP合酶活性不稳定。冻结和解冻肝质膜后,这种不稳定性增加了约2倍。蛋白酪氨酸磷酸酶抑制剂[钒酸盐,氟化物(50-100 mM)]稳定酶的活性,但蛋白酶抑制剂不能稳定酶的活性,这表明酶的失活与蛋白酪氨酸的去磷酸化有关。环状PIP合酶存在于所有测试的组织中,例如脑,心脏,肠,肾,肝,肺,骨骼肌,脾脏和睾丸。除肝脏外,大多数组织中的环状PIP合酶活性相当低,但是当均质化缓冲液中存在蛋白质酪氨酸磷酸酶抑制剂(如钒酸盐)时,其循环活性可以提高至5倍。酪氨酸激酶src激酶将肝质膜上的环状PIP合酶预孵育会导致环状PIP合酶活性增加2倍,尽管这肯定不是src激酶在完整细胞中发挥的生理作用。数据表明,环状PIP合酶可以通过两种独立的机制激活:G蛋白或蛋白酪氨酸磷酸化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号